🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

91 results for “Bristol-Myers Squibb / Pfizer EEIG” Clear

  1. OSIMERTINIB MESYLATE, OSIMERTINIB MESYLATE, PEMBROLIZUMAB, BL-B01D1

    Bristol-Myers Squibb / Pfizer EEIG

    Advance solid tumors

    phase 2 small molecule active

    1 trial

  2. Oxaliplatin 5 mg/ml concentrate for solution for infusion, TEMOZOLOMIDE, TRAMETINIB, DISODIUM FOLINATE, Capecitabine Accord 300 mg film-coated tablets, Temozolomide SUN 5 mg hard capsules, RUCAPARIB, Mekinist 0.5 mg film-coated tablets, Temozolomide SUN 140 mg hard capsules, REGORAFENIB, Capecitabine Accord 300 mg film-coated tablets, TEMOZOLOMIDE, TEMOZOLOMIDE, Temozolomide SUN 20 mg hard capsules, RUCAPARIB, CABOZANTINIB, Capecitabine Accord 300 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets,

    Bristol-Myers Squibb / Pfizer EEIG

    Pan tumor

    phase 2 small molecule active

    1 trial

  3. PEMETREXED DISODIUM, PACLITAXEL, CARBOPLATIN, CISPLATIN, PACLITAXEL ALBUMIN-BOUND, Relatlimab, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Bristol-Myers Squibb / Pfizer EEIG

    Non small Cell Lung cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  4. Placebo for bms-986435-01

    Bristol-Myers Squibb / Pfizer EEIG

    Heart failure with preserved ejection fraction (HFpEF)

    phase 2 small molecule active

    1 trial

  5. TEMOZOLOMIDE, TEMOZOLOMIDE, TOCILIZUMAB, CALCIUM FOLINATE, CYCLOPHOSPHAMIDE, RITUXIMAB, Lisocabtagene maraleucel, TEMOZOLOMIDE, PROCARBAZINE, FLUDARABINE, METHOTREXATE, TEMOZOLOMIDE, CALCIUM FOLINATE

    Bristol-Myers Squibb / Pfizer EEIG

    Primary Central Nervous System Lymphoma

    phase 2 small molecule active

    1 trial

  6. anti-IL8 mAb, Ipilimumab, anti-IL8 mAb, 5% dextrose solution for injection, OPDIVO 10 mg/mL concentrate for solution for infusion., Ipilimumab, 0.9% sodium chloride solution for injection

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced solid tumors

    phase 2 small molecule active

    1 trial

  7. farletuzumab ecteribulin

    Bristol-Myers Squibb / Pfizer EEIG

    Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  8. linrodostat mesylate; IDO1 inhibitor, linrodostat mesylate; IDO1 inhibitor, Ipilimumab, Relatlimab intravenous, OPDIVO 10 mg/mL concentrate for solution for infusion., linrodostat mesylate; IDO1 inhibitor, Ipilimumab

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced Malignant Tumors

    phase 2 small molecule active

    1 trial

  9. A PET Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants

    Bristol-Myers Squibb / Pfizer EEIG

    Neuropsychiatric indications and potentially other conditions

    phase 1 other active

    1 trial

  10. A Phase 1 Randomized Study to Evaluate the Effect of Food on the Bioavailability of BMS-986158 in Participants with Advanced Solid Tumors.

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  11. A Phase 1 Study of BMS-986406 as Monotherapy and in Combination in Advanced Tumors

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced Malignant Tumors

    phase 1 other active

    1 trial

  12. A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced or metastatic solid tumors, Gastroesophageal cancer (GEC), High grade serous ovarian cancer (HGSOC), Endometrial cancer (EC), Advanced or metastatic breast cancer, Platinum-resistant ovarian cancer (PROC)

    phase 1 other active

    1 trial

  13. A Phase 1 Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants with Severe, Refractory Autoimmune Diseases

    Bristol-Myers Squibb / Pfizer EEIG

    Systemic Sclerosis, Idiopathic Inflammatory Myopathy, Rheumatoid Arthritis, Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  14. A Phase 1/1b First-in-Human Study of BMS-986506 in ccRCC

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced Clear Cell Renal Cell Carcinoma

    phase 1 other active

    1 trial

  15. A Phase I Study of BMS-986497 alone or in combination with Azacitidine (Aza) and Azacitidine plus Venetoclax (AZA+VEN) in relapsed or refractory (R/R) AML or MDS

    Bristol-Myers Squibb / Pfizer EEIG

    Acute Myeloid Leukemia and Myelodysplastic Syndrome

    phase 1 other active

    1 trial

  16. Multiple Ascending Doses of BMS-986326 in Participants with Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus, or Systemic Lupus Erythematosus

    Bristol-Myers Squibb / Pfizer EEIG

    Subacute Cutaneous Lupus Erythematosus, Discoid Lupus Erythematosus, Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  17. Study of Repotrectinib and CYP450 probe Cocktail in Patients with locally advanced or Metastatic Tyrosine Kinase Inhibitors (TKI)-Pretreated ROS1-Positive Non-small Cell Lung Cancer (NSCLC)

    Bristol-Myers Squibb / Pfizer EEIG

    Non-small Cell Lung Cancer (NSCLC)

    phase 1 other active

    1 trial

  18. [14C]-BMS986504 Mass Balance Study in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion

    Bristol-Myers Squibb / Pfizer EEIG

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  19. USTEKINUMAB, USTEKINUMAB, deucravacitinib

    Bristol-Myers Squibb / Pfizer EEIG

    Moderate to Severe Plaque Psoriasis

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources